Navigation Links
ViroPharma Announces Discontinuation of HCV-796 Development
Date:4/16/2008

EXTON, Pa., April 16 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) announced today that ViroPharma and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), have jointly discontinued the development of HCV-796 due to the previously announced safety issue that emerged in the ongoing Phase 2 trial in patients with hepatitis C.

"Clearly, this is a disappointing outcome for patients suffering from this difficult disease," commented Vincent Milano, ViroPharma's president and chief executive officer. "Significant activities were undertaken to determine a clear path forward for HCV-796; however, the risk associated with potential hepatotoxicity ultimately posed too high of a hurdle to merit further development."

The companies will ensure that patients enrolled in the ongoing Phase 2 study will continue to receive the current standard of care. ViroPharma also announced that ViroPharma and Wyeth do not expect to continue to collaborate on future development of hepatitis C treatment candidates.

About ViroPharma Incorporated

ViroPharma Incorporated is committed to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R) approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. ViroPharma to Present at Three Upcoming Healthcare Conferences
2. ViroPharma to Present at the Natixis Bleichroeder Conference
3. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... , June 30, 2015 Pulse Light ... a survey to Rosacea sufferers as part of their ongoing ... Rosacea sufferers found effective for their Rosacea. The survey participants ... comprised 47% men and 53% women. The results ... participants did not consider or attempt to visit their GP ...
(Date:6/30/2015)... , June 30, 2015  Ardelyx, Inc. (NASDAQ: ... cardio-renal, gastrointestinal and metabolic diseases, today announced that the ... 14, 2015, from 8:00 a.m.- 1:00 pm EDT in ... The Ardelyx senior management team will present an ... compound, tenapanor, which has completed Phase 2b clinical trials ...
(Date:6/30/2015)... , BERKELEY, Kalifornien, und KOPENHAGEN, Dänemark, ... Biologics, Inc. , ein Weltmarktführer der klinischen ... anderen therapeutischen Proteinen, gab heute bekannt, dass ... der Produktionskapazität den Ausbau der nordamerikanischen Produktionsanlage ... mit der Ergänzung  einer Einweg-Anlage Bioreactor 6Pack™ ...
Breaking Medicine Technology:84% of Rosacea Sufferers Say NHS Treatments Were "Ineffective" New Survey Reveals 284% of Rosacea Sufferers Say NHS Treatments Were "Ineffective" New Survey Reveals 3Ardelyx to Host Inaugural R&D Investor Day in New York City on July 14, 2015 2CMC Biologics baut GMP-Produktionskapazität in den USA aus 2CMC Biologics baut GMP-Produktionskapazität in den USA aus 3
... Mass., Oct. 26, 2011 Idenix Pharmaceuticals, Inc. (NASDAQ: ... financial results for the third quarter of 2011 on Wednesday, ... Idenix management will host a conference call at 4:30 p.m. ... financial results for the third quarter of 2011 and provide ...
... MECHANICSBURG, Pa., Oct. 26, 2011 One out of three ... according to an Opinion Research/Select Medical telephone poll. Against that ... a statement today reminding the American public that influenza season ... chronic lung disease such as asthma or COPD (Chronic Obstructive ...
Cached Medicine Technology:Idenix to Host Conference Call Discussing Third Quarter and Nine Month 2011 Financial Results and Announces Presentations at the American Association for the Study of Liver Diseases Meeting (AASLD) 2Poll: One Out of Three U.S. Adults Not Planning to Get Flu Shot This Year 2
(Date:6/30/2015)... York (PRWEB) , ... June 30, 2015 , ... ... http://www.xareltolawsuit2015.com/ ) currently pending in a federal multidistrict litigation now underway in the ... convenes its next monthly Status Conference. According to the Court’s calendar, that conference ...
(Date:6/30/2015)... Orem, Utah (PRWEB) , ... June 30, 2015 , ... ... that it has restructured its management team and added a new CEO, Mr. Darold ... and industry leading selection of premium essential oils that customers have come to know ...
(Date:6/30/2015)... ... 30, 2015 , ... Allied Anesthesia physicians are committed to ... to help provide free outpatient procedures to some of Orange County’s neediest residents ... Center. , The event was coordinated by AccessOC, which was founded in ...
(Date:6/30/2015)... ... June 30, 2015 , ... MJH Associates today ... Healthcare Research & Analytics , a consultative healthcare market research practice that is ... businesses. HRA offers quantitative and qualitative, custom and multi-client primary market research services ...
(Date:6/30/2015)... ... ... Red Hot & Blue Restaurants, Inc. took home the “Best Burger ... was selected as “Best BBQ” in a Texas-based Living Magazine Reader’s Choice ... Randy McCann said, “Everyone knows Red Hot & Blue serves smokin’ fresh Barbecue (smoked ...
Breaking Medicine News(10 mins):Health News:Progress of Federal Xarelto Lawsuits Pending in Multidistrict Litigation to Be Discussed During July 9th Status Conference 2Health News:Progress of Federal Xarelto Lawsuits Pending in Multidistrict Litigation to Be Discussed During July 9th Status Conference 3Health News:Rocky Mountain Oils Adds New CEO, Announces Relocation of Operations to Orem, Utah 2Health News:Allied Anesthesia Physicians Volunteer to Help Orange County’s Uninsured During Annual Super Surgery Saturday 2Health News:Allied Anesthesia Physicians Volunteer to Help Orange County’s Uninsured During Annual Super Surgery Saturday 3Health News:HRA Healthcare Research & Analytics Welcomes 'Creative Problem Solver' as New Executive Vice President 2Health News:HRA Healthcare Research & Analytics Welcomes 'Creative Problem Solver' as New Executive Vice President 3Health News:Red Hot & Blue BBQ Restaurants Voted "Best Burger" in Virginia and "Best Barbecue" in Texas 2Health News:Red Hot & Blue BBQ Restaurants Voted "Best Burger" in Virginia and "Best Barbecue" in Texas 3
... most of their genes, including 70 percent of all ... evolutionary conservation, researchers at the Salk Institute for Biological ... for an innovative study of gliomas, the most common ... but we still know very little about the underlying ...
... Results are better with brief immobilization than with bandage or ... People with severe ankle sprains recover faster with a short ... brace than with the use of either a tubular compression ... , Along with receiving one of the four ...
... 12 On March 1st, Insight Psychological Centers, LLC ... Partial Hospitalization Program (PHP) for anxiety and mood disorders. ... in Chicago, Insight,s intensive program will be offered in ... to work, avoid taking disability leave, and continue participating ...
... Dr. Marvin Berlin is out to,change lives by ... as he,hosts the latest event for Dentistry From The ... event will take place on Saturday, Feb. 14 at,McKinneyDentist.com ... his,partners, including Dr. Matthew Markham, Dr. Jeff Lynch, and ...
... Pennsylvania Department of Health has reviewed and approved ... in Brownsville, Fayette County, which ceased operations today.All ... been relocated to other facilities. All hospital staff, ... assisted with the patient transfer.Local ambulances and emergency ...
... Inc, an,emerging specialty pharmaceutical company dedicated to reducing ... preliminary,findings from its development and testing of an ... in Charleston,s clinical trials. , ... test the feasibility and,reliability of the OSQ," reported ...
Cached Medicine News:Health News:Fruit flies soar as lab model, drug screen for the deadliest of human brain cancers 2Health News:Fruit flies soar as lab model, drug screen for the deadliest of human brain cancers 3Health News:Casting Seems Best for Severe Ankle Sprains 2Health News:New Anxiety and Mood Disorders Intensive Treatment Program in Downtown Chicago 2Health News:McKinneyDentist.com Hosts Free Day of Dentistry With Dentistry From The Heart 2Health News:Charleston Conducts Evaluation of an Opioid Symptoms Questionnaire 2
... are an ophthalmologic medical device designed for ... -1.00 to -3.00 diopters.* When placed in ... central optical zone, the product reshapes the ... is composed of two prescription inserts, each ...
... is our most affordable basic centrifuge. The 614 is ... 614 is also the quietest small lab centrifuge on ... up to six (6) test tubes up to 15ml ... lid safety switch and is UL/CSA compliant. ...
... is a simple one, help physicians serve ... image, the physician is provided with significantly ... structures. This technical accomplishment is combined with ... The device features: ...
... Contour Eyelid Implants feature a proprietary ... of the ocular globe. The Contour ... in the eyelid because the tapered lower ... lower profile. Surfaces and edges of the ...
Medicine Products: